The Annals Evolution of Clinical Pharmacy | Now Available
home help contact us subscription past issues search current issue
 QUICK SEARCH:   [advanced]


     



Published Online, 3 November 2009, www.theannals.com, DOI 10.1345/aph.1M324.
This Article
Right arrow PDF
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Google Scholar
Right arrow Articles by Schutt, A. C
Right arrow Articles by Bohm, N. M
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schutt, A. C
Right arrow Articles by Bohm, N. M


CASE REPORTS

Multidrug-Resistant Enterococcus faecium Endocarditis Treated with Combination Tigecycline and High-Dose Daptomycin (December)

Amanda C Schutt PharmD1 Nicole M Bohm PharmD BCPS2*

1 at time of writing, Internal Medicine Specialty Resident, PGY-2, College of Pharmacy Residency Program, Medical University of South Carolina, Charleston, SC; now, Clinical Pharmacist, Internal Medicine, Carilion Clinic, Roanoke Memorial Hospital, Roanoke, VA
2 Internal Medicine Clinical Specialist, Department of Pharmacy, Medical University of South Carolina, Charleston, SC

* To whom correspondence should be addressed. E-mail: bohm{at}musc.edu.


   Abstract

OBJECTIVE: To report a case of multidrug-resistant Enterococcus faecium requiring combination antibacterial therapy.

CASE SUMMARY: A 39-year-old female presented with chest pain and a history of endocarditis 3 years prior to admission. Blood cultures were positive for E. faecium. She was treated initially with daptomycin 6 mg/kg daily, which was later increased to 8 mg/kg daily despite poor gentamicin clearance. A variety of antibiotics were used in combination with daptomycin, but the patient remained febrile, with positive blood cultures revealing vancomycin minimum inhibitory concentration (MIC) greater than 256 μg/mL and daptomycin MIC 3 μg/mL (and later, 4 μg/mL). Following the addition of tigecycline, the patient experienced rapid clinical and microbiologic improvement, and blood cultures remained negative 9 weeks after discharge.

DISCUSSION: Limited clinical data support the use of daptomycin for the treatment of E. faecium endocarditis, and information regarding the effects of escalating doses and combination therapy is scant. After failing multiple combination regimens, this patient responded to a combination of tigecycline and daptomycin. Daptomycin 8 mg/kg daily did not result in creatine kinase elevation in the face of evidence of possible renal dysfunction.

CONCLUSIONS: Increasing doses of daptomycin may enhance efficacy without compromising safety, even in patients with some renal dysfunction. The combination of daptomycin and tigecycline may be useful for the treatment of multi-drug- resistant E. faecium.

Key Words: daptomycin, endocarditis, Enterococcus, tigecycline.

Reprints: Dr. Bohm, Medical University of South Carolina Department of Pharmacy, 50 Ashley Ave., PO Box 250584, Charleston, SC 29425, fax 843/792-0566, bohm@musc.edu







homecopy help contact us subscription past issues search current issue
Copyright © 2009 by Harvey Whitney Books Company.